Most Recent
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a "commercial outcome for a patentee".
A judge has slammed Novartis for putting forward four "overlapping" experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a "hot tub".
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck's patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an "untenable" patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.
Swiss drug giant Novartis has secured an injunction temporarily blocking drug maker Pharmacor from launching a generic version of the company’s top-selling MS drug Gilenya in Australia.
Swiss drug giant Novartis has sued generic drug maker Pharmacor to halt its launch of a generic version of the company's top-selling MS drug Gilenya.
Generic pharmaceutical company Sandoz has hit back in an intellectual property lawsuit by Merck Sharp & Dohme, filing a cross-claim that seeks to undo an extension of time granted to the US drug manufacturer for a patent relating to its multibillion dollar Januvia and Janumet diabetes drugs.